Corcept Therapeutics filings document the regulatory record of a commercial-stage pharmaceutical company focused on cortisol modulation. Recent Form 8-K reports cover operating results, Regulation FD corporate updates, FDA approval of Lifyorli, clinical-trial disclosures for relacorilant programs, patent-dispute developments involving Korlym and material distribution arrangements for Korlym and authorized generic mifepristone.
The company’s proxy materials describe board matters, executive compensation, equity awards and shareholder voting items. Its SEC record also identifies CORT common stock listed on Nasdaq and provides formal disclosures on governance, capital structure, business risks, product regulation, intellectual property and commercialization matters.
Corcept Therapeutics Inc. reported proposed sales of common stock by an affiliate under a Form 144 notice. The filing lists a 20,000-share sale associated with a stock option exercise on 06/02/2026 and several prior dispositions in March–May 2026.
The filings show prior reported sales of 20,000 shares on 04/08/2026 for $819,453.00, 8,233 shares on 03/04/2026 for $296,346.00, 11,767 shares on 03/20/2026 for $423,707.00, and 20,000 shares on 05/06/2026 for $1,036,522.00. The broker listed is Stifel Nicolaus & Company Inc.
CORT files a Rule 144 notice to sell 160,000 shares of Common Stock through Stifel Nicolaus & Company Inc. The filing references 160,000 shares, an amount of $11,200,016.00, and a Nasdaq listing with a date entry of 06/01/2026. The excerpt also lists prior stock option exercises of 95,833 (02/02/2022) and 64,167 (02/13/2023).
Corcept Therapeutics Inc. submitted a Form 144 notice relating to proposed sales of common stock. The filing lists a stock option exercise dated 07/06/2022 and broker information for Stifel Nicolaus & Company. It also records recent dispositions by Joseph K. Belanoff of 26,198 shares on 03/25/2026 for $1,311,825 and 40,000 shares on 05/01/2026 for $2,003,858.
Corcept Therapeutics executive Joseph Douglas Lyon reported an open-market sale of 5,000 shares of Common Stock at $65.00 per share on May 27, 2026. After this transaction, he directly owns 6,230 shares of Corcept stock.
A footnote states that his holdings include shares underlying unvested restricted stock awards, including 749 shares granted on June 2, 2025, 200 shares granted on September 2, 2025, 178 shares granted on December 1, 2025, and 398 shares granted on March 2, 2026. These restricted stock awards are scheduled to vest on the one-year anniversary of each grant date if specified conditions are met.
Corcept Therapeutics officer Sean Maduck reported an option exercise and related share sales. He exercised stock options for 75,000 shares of common stock at a $8.27 exercise price, then sold 20,425 shares at $66.1599 and 54,575 shares at $65.3711 in open-market transactions.
The filing notes these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 8, 2025. After the transactions, he held 29,402 shares directly, plus additional indirect holdings through trusts and LLCs associated with him, which include restricted stock awards that vest over time.
Corcept Therapeutics director James N. Wilson reported indirect gifts of company stock made through family entities. Entities associated with Wilson, including a family trust and James and Pamela Wilson Family Partners, made bona fide gifts totaling 910,078 shares of Corcept common stock at no consideration.
Following these transactions, the James N. Wilson and Pamela D. Wilson Trust held 1,104,543 shares indirectly, and two 2025 Grantor Retained Annuity Trusts each held 200,000 shares. Wilson has voting power over certain shares via voting agreements but disclaims beneficial ownership except to the extent of his pecuniary interest.
Corcept Therapeutics Incorporated reported results of its 2026 annual stockholder meeting and an update to its equity compensation plan. Stockholders approved an amendment to the 2024 Incentive Award Plan, increasing the shares available under the plan by 8,000,000 shares, with the amended plan effective upon approval on May 21, 2026.
All eight director nominees were elected, and stockholders ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. Stockholders also approved, on an advisory basis, the compensation of the company’s named executive officers and the amended incentive plan, with 53,163,364 votes for, 23,867,363 against, and 263,730 abstentions on the plan proposal.
Corcept Therapeutics director Leonard G. Baker Jr received a grant of stock options covering 12,500 shares of common stock on May 21, 2026. The options have an exercise price of $59.69 per share and expire on May 21, 2036. They vest in equal monthly installments over one year starting on the monthly anniversary of May 21, 2026, contingent on his continued service, and represent equity-based compensation rather than an open-market trade.
Corcept Therapeutics director Gregg H. Alton received a new stock option award covering 12,500 shares of common stock. The options have an exercise price of $59.69 per share and expire on May 21, 2036, providing long-term equity-based compensation.
The grant vests ratably in equal installments on each monthly anniversary of May 21, 2026 over a one-year period, and each vesting tranche is conditioned on his continued service as of the relevant monthly vesting date.